Efficacy of α-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring

Journal of Diabetes Investigation

Volumn 4, Issue 4, 2013, Pages 393-398

  Kurozumi, Akira ^a   Okada, Yosuke ^a   Mori, Hiroko ^a   Arao, Tadashi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Alpha glucosidase inhibitor; Continuous glucose monitoring; Dipeptidyl peptidase 4 inhibitor

Indexed keywords

ALOGLIPTIN; GLUCOSE; MIGLITOL; VOGLIBOSE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERGLYCEMIA; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 84880140915     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12059     Document Type: Article

References (22)

1. Glucose tolerance mortality: comparison of WHO American Diabetes Association diagnostic criteria. The DECODE study group, European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet 1999; 354: 617-621.
2. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose, The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924.
3. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
4. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21-33.
5. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.
6. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus; the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.
7. Ceriello A, Colaqiuri S, Gerich J, et al. Guideline for management of postmeal glucose. Nutur Metab Cardiovasc Dis 2008; 18: 17-33.
8. Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 2008; 25: 1151-1156.
9. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagons-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002; 4: 329-335.
10. Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagons-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 2009; 26: 667-672.
11. Mori Y. Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents. Nippon Rinsho 2011; 69: 1505-1514 (Japanese).
12. Boyne MS, Silver DM, Kaplan J, et al. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003; 52: 2790-2794.
13. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33 (Supp 1): 11-61.
14. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
15. Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patient. Diabetes Obes Metab 2012; 14: 283-287.
16. van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163.
17. Fukase N, Takahashi H, Manaka H, et al. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion. Diabetes Res Clin Pract 1992; 15: 187-195.
18. Goke B, Fuder H, Wieckhorst G, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995; 56: 493-501.
19. Tsujino D, Nishimura R, Taki K, et al. Comparative efficacy of α-glucosidase inhibitors in suppressing postprandial hyper-glycemia: an assessment by continuous glucose monitoring-The MAJOR Study. Diabetes Technol Ther 2010; 13: 303-308.
20. Kadowaki T, Ishibashi S, Sakura H, et al. Diabetology basic and clinical. Nishimura, Tokyo, 2007: 945-948 (Japanese).
21. Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increase active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010; 12: 224-233.
22. Takeda pharmaceutical drug company. Alogliptin package insert, interview form 2011. (Japanese)